Key facts
- Faks’s last known valuation is $17.7M (Mar 2025).
- It has raised $11.9M; the latest was Seed Round ($6.3M) in Mar 2025.
- Notable investors include FJ Labs, Kima Ventures, Speedinvest, Seedcamp, Super Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Faks
- ·The full record, as it builds
Funding rounds
No funding rounds for Faks are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Faks
Developer of a mobile application designed to facilitate simplified exchange between pharmacists and laboratories. The company's application offers features that include managing complaints, processing returns of expired medications, and coordinating commercial operations, all within a single interface, and assists laboratories in overseeing customer relations, enhancing client satisfaction, and improving commercial efficiency, enabling pharmacy owners and staff to handle supplier relations efficiently.
- Sector
- Information Technology
- HQ
- Paris, France
- Founded
- 2020
- Employees
- 34
- Website
- faks.co/
- Ownership
- Privately Held (backing)
Faks doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Faks shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Faks in its N-PORT filings yet. We sweep new filings monthly.